FDA guidance delays increase by 20% under new commissioner
user-generated· regulatory
FDA guidance delays increase by 20% under new commissioner
Market overview
Drug approval timelines will extend by an average of 20% in the first 12 months under the new FDA commissioner due to increased scrutiny and guideline revisions. This contradicts short-term market optimism.
regulatory prediction market
- Implied probability (Yes)
- 55%
Source: user-generated
More regulatory markets
- Crypto billionaire Harborne faces FCA scrutiny over £5m gift — 55% Yes
- Crypto billionaire Harborne will face FCA scrutiny — 60% Yes
- Crypto billionaire Christopher Harborne’s donation triggers FCA inquiry into funding transparency — 70% Yes
- Crypto billionaire Christopher Harborne will face parliamentary scrutiny over £5m gift — 55% Yes
- Harborne crypto holdings face regulatory scrutiny — 60% Yes
- SEC approves at least 2 new Bitcoin ETFs by Q4 2027 — 75% Yes
- SEC approves Kalshi's crypto futures products by 2026-Q3 — 55% Yes
- Iran's central bank bans crypto mining by 2027 Q1 — 85% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…